➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Moodys
Harvard Business School
Express Scripts
Johnson and Johnson

Last Updated: October 16, 2021

DrugPatentWatch Database Preview

Litigation Details for Teva Pharmaceuticals International GmbH v. Eli Lilly and Company (D. Mass. 2018)


Email this page to a colleague

« Back to Dashboard

Biologic Drugs cited in Teva Pharmaceuticals International GmbH v. Eli Lilly and Company
The biologic drug covered by the patent cited in this case is ⤷  Free Forever Trial .

Details for Teva Pharmaceuticals International GmbH v. Eli Lilly and Company (D. Mass. 2018)

Date Filed Document No. Description Snippet Link To Document
2018-09-27 1 THE PATENTS-IN-SUIT A. U.S. Patent No. 8,586,045 46. On November…November 19, 2013, United States Patent No. 8,586,045 (“the ’045 patent”), …innovations are protected by at least U.S. Patent Nos. 8,586,045; 8,597,649; 9,266,951; 9,340,614; 9,346,8819,890,210; and 9,890,211 (“the Patents-in-Suit”). Labrys assigned the Patents-in-Suit to Teva on September…Infringes The Patents-in-Suit. 26. Eli Lilly tracks and follows Teva’s patents related to the External link to document
2021-02-23 101 Memorandum & Order nine patents: U.S. Patent Nos. 8,586,045 (“the ’045 patent”); 8,597,649 (“the ’649 patent”); 9,…9,266,951 (“the ’951 patent”); 9,340,614 (“the ’614 patent”); 9,346,881 (“the ’881 patent”); 9,884,9079,884,907 (“the ’907 patent”); 9,884,908 (“the ’908 patent”); 9,890,210 (“the ’210 patent”); and 9,890,211 …migraines, does not infringe Teva’s patents and that Teva’s patents are invalid. [ECF No. 17]. The parties…9,890,211 (“the ’211 patent”). [ECF No. 65 at 7, 8 n.3; ECF No. 66 at 6]. Six of the patents claim as inventive External link to document
2019-04-22 43 Memorandum & Order U.S. Patents Nos. 8,586,045 (“’045 Patent”); 8,597,649 (“’649 Patent”); 9,266,951 (“’951 Patent”); 9,…that the ’649 Patent, ’951 Patent, ’614 Patent, ’881 Patent, ’210 Patent, and ’211 Patent were invalid…the 5 The ’045 Patent, ’649 Patent, ’951 Patent, ’614 Patent, and ’881 Patent were issued to Labrys…(“’614 Patent”); 9,346,881 (“’881 Patent”); 9,884,907 (“’907 Patent”); 9,884,908 (“’908 Patent”); 9,890,210…22, 1-23, 1-24]. The ’907 Patent, ’908 Patent, ’210 Patent, and ’211 Patent were issued to Teva GmbH as External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
McKinsey
Medtronic
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.